Bristol Myers Squibb (BMY) announced positive top-line results from the ongoing, ex-US, Phase 2 registrational study evaluating Reblozyl (luspatercept-aamt) versus placebo for anemia in adults with Alpha (β)-Thalassemia.

• "The non‑transfusion‑dependent (NTD) and transfusion‑dependent (TD) cohorts of the study met their respective primary endpoints, with Reblozyl demonstrating a statistically significant and clinically meaningful increase in hemoglobin levels in NTD patients with β‑thalassemia, and a statistically significant and clinically meaningful decrease in red blood cell (RBC) transfusion burden in TD patients with β‑thalassemia.
• The study also met all key secondary endpoints. 
• Safety findings were consistent with the known profile of Reblozyl in thalassemia.

Bristol Myers Squibb's positive results from their Phase 2 trial of Reblozyl for anemia in adults with Alpha-thalassemia mark a significant achievement, suggesting potential for increased market confidence in the drug's effectiveness. The met primary and secondary endpoints imply a strong outlook for future regulatory approval and could enhance the company's product pipeline, making it a key driver of stock performance in the pharmaceuticals sector.